Uncategorized - February 4, 2014
Biotech Umeå Investment Day in Stockholm
In the end of January, investors and companies from the Umeå region met with Scandinavian and international representatives for partnering meetings. On January 30, Biotech Umeå Investment Day took place at Grand Hôtel in Stockholm. The day started with partnering sessions between companies from the Umeå region and investors and business angels from Scandinavia and abroad […]
Biotech article - February 4, 2014
Norway invests in biotech
The Research Council of Norway has allocated NOK 454 million in funding over four years to projects in the ICT sector, biotechnology and biomedicine. In total, 58 companies were awarded funding, and over one third of these were first-time applicants for Research Council funding. “It is a very good sign that we have received so many excellent […]
In a new job - February 3, 2014
New CEO for Bioarctic Neuroscience
Gunilla Osswald has been appointed as the company’s new CEO. Osswald joined BioArctic in February 2013 as Deputy CEO. She was recruited from AstraZeneca where she was working as VP for Neurodegenerative disorder projects. According to Bioarctic, the new CEO has vast experience in leadership and drug development in neuroscience. In a press release from the […]
MedTech Business - February 3, 2014
Xvivo expands US study
Barnes Jewish Hospital in St Louis is the tenth transplant center to participate in the Swedish medtech company Xvivo’s NOVEL trial. The NOVEL trial is designed to evaluate the effect of the product Steen Solutions in increasing the amount of usable lungs in the donor pool. The study is being performed at 10 centers in […]
Acquisition - February 3, 2014
AstraZeneca completes acquisition of BMS diabetes share
AstraZeneca has completed the acquisition of the entirety of Bristol-Myers Squibb’s interest in the companies’ diabetes alliance. In December last year, the news about the acquisition were announced and on February 1 2014 the deal was completed. According to the agreement, AstraZeneca gets ownership of the intellectual property and global rights for the development, manufacture and […]
Drug Development Pharma - January 31, 2014
AstraZeneca joins cancer consortium
Together with DKFZ and EORTC, AstraZeneca has joined the Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine. WIN is a lobal network of academics, industries, payors and patient advocacy organizations which goal is to significantly improve survival and quality of life of cancer patients in the next three years. It was initiated in 2010 with leadership from the […]
